Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252810 · ClinicalTrials.gov registry record · Phase 2
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
A Phase 2 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 284
- Enrollment target
NCT01252810: Completed Phase 2 study, sponsored by GE Healthcare.
NCT01252810 is a Phase 2 study that has completed, run by GE Healthcare. The registered enrollment target is 284 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01252810, a Phase 2 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 284 participants
- Enrollment target
Study Summary
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.
Primary Outcome
Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.
Interventions
- DRUG GE-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01252810 record still lists
NCT01252810 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 1 intervention - of which GE-145 is the first listed.
NCT01252810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01252810 about?
NCT01252810 is a clinical study titled "Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure". To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class...
What is the current status of trial NCT01252810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 284 participants. The study started on 2010-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01252810?
The interventions under investigation include: GE-145 (DRUG).
Who is sponsoring clinical trial NCT01252810?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01252810's enrollment target sits among peer trials
284 195th of 2000 higher than 1,806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia